RxDoctor Payments Data

Steven Nakano, MD

Neurology · Sacramento, CANPI 1053793760

Payments from drug & device makers

$7,381in general payments, 2019–2025

Across 111 payments — averaging $66.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • AbbVie$822
  • Acadia Pharmaceuticals Inc$439
  • Abbott$212
  • Amneal Pharmaceuticals LLC$203
  • Adamas Pharmaceuticals, Inc.$190
  • plus $779 from 9 others

What the payments were for

  • Speaking & faculty fees$461%
  • Grants$4,00054%
  • Travel & lodging$2904%
  • Food & beverage$3,04641%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,381 in reported general payments places this provider in the 65th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$274,545
Medicare patients
276
Services billed
22,347

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate41$242,908
RytaryCarbidopa/Levodopa71$128,833
IngrezzaValbenazine Tosylate12$94,240
BotoxOnabotulinumtoxina36$55,309
NourianzIstradefylline14$40,447
Nurtec OdtRimegepant Sulfate26$34,139
UbrelvyUbrogepant30$30,338
Rasagiline Mesylate86$27,527
Droxidopa19$19,577
Carbidopa-LevodopaCarbidopa/Levodopa385$16,087
Emgality PenGalcanezumab-Gnlm21$15,525
QuliptaAtogepant14$15,220
Carbidopa-Levodopa ErCarbidopa/Levodopa221$11,927
Aimovig AutoinjectorErenumab-Aooe12$8,438
LinzessLinaclotide12$7,063

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$439$242,90841 claims
Amneal Pharmaceuticals LLCRytary$203$128,83371 claims
AbbVieBotox, Ubrelvy, Qulipta, Linzess$822$107,93092 claims
Kyowa Kirin, Inc.Nourianz$168$40,44714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,996 neurology providers in California.

Other neurology in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →